Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 May 1;80(3-4):483–488. doi: 10.1038/sj.bjc.6690382

Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade

C-W Wu 2,4, Y-Y Lin 1, G-D Chen 1, C-W Chi 3,4, D P Carbone 5, J-Y Chen 1,4
PMCID: PMC2362310  PMID: 10408857

Abstract

Mutation of the p53 tumour suppressor gene often leads to the accumulation of mutant p53 protein in tumour cells. Many cancer patients develop antibodies that recognize the overexpressed p53 protein. The presence of these antibodies is, in some tumour types, associated with poor prognosis. Gastric cancer is a highly prevalent disease associated with a high rate of mortality, there is a need for improved clinical and biological markers for disease behaviour. To investigate the clinical relevance of serum anti-p53 antibodies in patients with gastric adenocarcinoma, we have examined the sera of 501 gastric cancer patients for the presence of serum antibodies against the p53 protein. By immunoblotting analysis using a cell lysate containing overexpressed p53 protein as well as affinity-purified recombinant p53 protein as antigens, we have detected anti-p53 antibodies in 11.2% (61 of 501) of gastric cancer patients, but in none of 46 cancer-free individuals. The presence of anti-p53 antibodies was tightly associated with tumours of higher nuclear grade and lymph node metastasis, and a negative association was found between the presence of anti-p53 antibodies and survival. These results suggest that a preoperative test of serum anti-p53 antibodies in gastric cancer patients can be useful to identify subset of patients who may need gastrectomy with lymph node dissection and post-operative adjuvant therapy. © 1999 Cancer Research Campaign

Keywords: gastric adenocarcinoma, serum anti-p53 antibodies, lymph node metastasis, nuclear grade, poor prognosis

Full Text

The Full Text of this article is available as a PDF (117.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angelopoulou K., Diamandis E. P., Sutherland D. J., Kellen J. A., Bunting P. S. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer. 1994 Aug 15;58(4):480–487. doi: 10.1002/ijc.2910580404. [DOI] [PubMed] [Google Scholar]
  2. Ben-Mahrez K., Sorokine I., Thierry D., Kawasumi T., Ishii S., Salmon R., Kohiyama M. Circulating antibodies against c-myc oncogene product in sera of colorectal cancer patients. Int J Cancer. 1990 Jul 15;46(1):35–38. doi: 10.1002/ijc.2910460109. [DOI] [PubMed] [Google Scholar]
  3. Bourhis J., Lubin R., Roche B., Koscielny S., Bosq J., Dubois I., Talbot M., Marandas P., Schwaab G., Wibault P. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. J Natl Cancer Inst. 1996 Sep 4;88(17):1228–1233. doi: 10.1093/jnci/88.17.1228. [DOI] [PubMed] [Google Scholar]
  4. Caron de Fromentel C., May-Levin F., Mouriesse H., Lemerle J., Chandrasekaran K., May P. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int J Cancer. 1987 Feb 15;39(2):185–189. doi: 10.1002/ijc.2910390211. [DOI] [PubMed] [Google Scholar]
  5. Chen J. Y., Funk W. D., Wright W. E., Shay J. W., Minna J. D. Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences. Oncogene. 1993 Aug;8(8):2159–2166. [PubMed] [Google Scholar]
  6. Crawford L. V., Pim D. C., Bulbrook R. D. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer. 1982 Oct 15;30(4):403–408. doi: 10.1002/ijc.2910300404. [DOI] [PubMed] [Google Scholar]
  7. Davidoff A. M., Humphrey P. A., Iglehart J. D., Marks J. R. Genetic basis for p53 overexpression in human breast cancer. Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):5006–5010. doi: 10.1073/pnas.88.11.5006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Davidoff A. M., Iglehart J. D., Marks J. R. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3439–3442. doi: 10.1073/pnas.89.8.3439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Gabbert H. E., Müller W., Schneiders A., Meier S., Hommel G. The relationship of p53 expression to the prognosis of 418 patients with gastric carcinoma. Cancer. 1995 Sep 1;76(5):720–726. doi: 10.1002/1097-0142(19950901)76:5<720::aid-cncr2820760503>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  10. Kakeji Y., Korenaga D., Tsujitani S., Baba H., Anai H., Maehara Y., Sugimachi K. Gastric cancer with p53 overexpression has high potential for metastasising to lymph nodes. Br J Cancer. 1993 Mar;67(3):589–593. doi: 10.1038/bjc.1993.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kern S. E., Pietenpol J. A., Thiagalingam S., Seymour A., Kinzler K. W., Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science. 1992 May 8;256(5058):827–830. doi: 10.1126/science.1589764. [DOI] [PubMed] [Google Scholar]
  12. Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature. 1991 Jun 6;351(6326):453–456. doi: 10.1038/351453a0. [DOI] [PubMed] [Google Scholar]
  13. Lubin R., Schlichtholz B., Bengoufa D., Zalcman G., Trédaniel J., Hirsch A., Caron de Fromentel C., Preudhomme C., Fenaux P., Fournier G. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res. 1993 Dec 15;53(24):5872–5876. [PubMed] [Google Scholar]
  14. Lubin R., Zalcman G., Bouchet L., Trédanel J., Legros Y., Cazals D., Hirsch A., Soussi T. Serum p53 antibodies as early markers of lung cancer. Nat Med. 1995 Jul;1(7):701–702. doi: 10.1038/nm0795-701. [DOI] [PubMed] [Google Scholar]
  15. Motojima K., Furui J., Kohara N., Ito T., Kanematsu T. Expression of p53 protein in gastric carcinomas is not independently prognostic. Surgery. 1994 Nov;116(5):890–895. [PubMed] [Google Scholar]
  16. Peyrat J. P., Bonneterre J., Lubin R., Vanlemmens L., Fournier J., Soussi T. Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet. 1995 Mar 11;345(8950):621–622. doi: 10.1016/s0140-6736(95)90523-5. [DOI] [PubMed] [Google Scholar]
  17. Rosenfeld M. R., Malats N., Schramm L., Graus F., Cardenal F., Viñolas N., Rosell R., Torà M., Real F. X., Posner J. B. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. J Natl Cancer Inst. 1997 Mar 5;89(5):381–385. doi: 10.1093/jnci/89.5.381. [DOI] [PubMed] [Google Scholar]
  18. Sang B. C., Chen J. Y., Minna J., Barbosa M. S. Distinct regions of p53 have a differential role in transcriptional activation and repression functions. Oncogene. 1994 Mar;9(3):853–859. [PubMed] [Google Scholar]
  19. Schlichtholz B., Legros Y., Gillet D., Gaillard C., Marty M., Lane D., Calvo F., Soussi T. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res. 1992 Nov 15;52(22):6380–6384. [PubMed] [Google Scholar]
  20. Sorokine I., Ben-Mahrez K., Bracone A., Thierry D., Ishii S., Imamoto F., Kohiyama M. Presence of circulating anti-c-myb oncogene product antibodies in human sera. Int J Cancer. 1991 Mar 12;47(5):665–669. doi: 10.1002/ijc.2910470506. [DOI] [PubMed] [Google Scholar]
  21. Unger T., Nau M. M., Segal S., Minna J. D. p53: a transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J. 1992 Apr;11(4):1383–1390. doi: 10.1002/j.1460-2075.1992.tb05183.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Wild C. P., Ridanpä M., Anttila S., Lubin R., Soussi T., Husgafvel-Pursiainen K., Vainio H. p53 antibodies in the sera of lung cancer patients: comparison with p53 mutation in the tumour tissue. Int J Cancer. 1995 Jun 22;64(3):176–181. doi: 10.1002/ijc.2910640306. [DOI] [PubMed] [Google Scholar]
  23. Winter S. F., Minna J. D., Johnson B. E., Takahashi T., Gazdar A. F., Carbone D. P. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res. 1992 Aug 1;52(15):4168–4174. [PubMed] [Google Scholar]
  24. Wu C. W., Hsieh M. C., Lo S. S., Lui W. Y., P'eng F. K. Results of curative gastrectomy for carcinoma of the distal third of the stomach. J Am Coll Surg. 1996 Sep;183(3):201–207. [PubMed] [Google Scholar]
  25. Wu C. W., Hsieh M. C., Lo S. S., Tsay S. H., Li A. F., Lui W. Y., P'eng F. K. Prognostic indicators for survival after curative resection for patients with carcinoma of the stomach. Dig Dis Sci. 1997 Jun;42(6):1265–1269. doi: 10.1023/a:1018814426278. [DOI] [PubMed] [Google Scholar]
  26. Wu C. W., Hsieh M. C., Lo S. S., Tsay S. H., Lui W. Y., P'eng F. K. Relation of number of positive lymph nodes to the prognosis of patients with primary gastric adenocarcinoma. Gut. 1996 Apr;38(4):525–527. doi: 10.1136/gut.38.4.525. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Wu C. W., Hsieh M. J., Lo S. S., Tsay S. H., Lui W. Y., P'eng F. K. Lymph node metastasis from carcinoma of the distal one-third of the stomach. Cancer. 1994 Apr 15;73(8):2059–2064. doi: 10.1002/1097-0142(19940415)73:8<2059::aid-cncr2820730808>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  28. Würl P., Weigmann F., Meye A., Fittkau M., Rose U., Berger D., Rath F. W., Dralle H., Taubert H. Detection of p53 autoantibodies in sera of gastric cancer patients and their prognostic relevance. Scand J Gastroenterol. 1997 Nov;32(11):1147–1151. doi: 10.3109/00365529709002995. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES